首頁 > 市場調查報告書 > 製藥

婦科治療

月經症候群治療市場規模、佔有率和成長分析（按產品類型、藥物類型、分銷管道和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1913179

月經症候群治療市場規模、佔有率和成長分析（按產品類型、藥物類型、分銷管道和地區分類）－2026-2033年產業預測

Premenstrual Syndrome Treatment Market Size, Share, and Growth Analysis, By Product (Prescription and Over-the-Counter (OTC)), By Drug Type (Analgesics, Antidepressants), By Distribution Channel, By Region-Industry Forecast 2026-2033.

出版日期: 2025年12月30日 | 出版商:

SkyQuest | 英文 189 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球月經症候群 (PMS) 治療市場規模預計在 2024 年達到 19.5 億美元，從 2025 年的 14.9 億美元成長到 2033 年的 19.5 億美元，在預測期（2026-2033 年）內複合年成長率為 3.42%。

全球月經症候群 (PMS) 治療市場正經歷成長，這主要得益於人們對 PMS 及其對女性健康影響的認知不斷提高，以及對有效治療方法的需求日益成長。與醫療保健領域向個人化、非侵入性治療轉變的大趨勢相呼應，非荷爾蒙療法療法和綜合療法已顯著增加。各大製藥和醫療保健公司正積極投資研發，以推出創新治療方法。然而，該市場也面臨許多挑戰，包括阻礙治療方法核准和普及的監管壁壘，以及治療通訊協定的不一致導致患者療效的差異。隨著 PMS 管理行動應用程式等數位健康解決方案的日益普及，資料隱私和安全問題變得至關重要。隨著產業技術融合的發展，確保強而有力的資料保護將發揮關鍵作用。

全球月經綜合症治療市場按產品、藥物、通路和地區進行細分。依產品分類，市場分為處方藥和非處方藥（OTC）。依藥物分類，市場分為止痛藥、抗憂鬱劑、口服避孕藥和卵巢抑制劑。按分銷管道分類，市場分為藥房/零售藥房、醫院藥房和線上藥房。按地區分類，市場分析涵蓋北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球月經症候群治療市場成長要素

人們對月經症候群 (PMS) 及其症狀的認知不斷提高，顯著推動了市場對治療方法的需求。宣傳宣傳活動和教育活動在提高女性對 PMS 的了解、並最終鼓勵她們尋求醫療幫助方面發揮關鍵作用。諸如國際月經症候群協會 (IAPMD) 等致力於解決此問題的組織，正積極進行宣傳活動，引導女性尋求醫療保健服務。 PMS 診斷率的提高導致對包括口服避孕藥在內的各種治療方法的需求增加，從而促進了全球月經治療市場的擴張。

限制全球月經症候群治療市場的因素

全球月經治療市場面臨許多挑戰，其中包括由於社會對經前症候群相關心理健康問題的污名化，導致症狀報告率偏低。在許多文化中，女性談論經前症候群及其相關症狀仍被視為禁忌，這使得她們不願尋求治療或公開談論自身症狀。這種文化上的抵觸情緒降低了對有效治療方法（如抗憂鬱症和荷爾蒙療法）的需求，從而阻礙了市場整體成長。因此，提高公眾意識和促進社會接納對於克服這些障礙、擴大患者的治療選擇至關重要。

全球月經症候群（PMS）治療市場趨勢

全球月經症候群 (PMS) 治療市場正經歷著向天然和整體療法的顯著轉變，消費者越來越傾向於選擇草藥和植物來源治療方法而非傳統藥物。這一趨勢反映了人們健康意識的增強，以及對非藥物替代療法以緩解經前症候群症狀（例如月經和情緒波動）的需求。添加維生素 B6、鈣和鎂等天然成分不僅吸引了尋求永續選擇的消費者，也推動了創新草藥療法市場的成長。抓住這一需求的公司正在蓬勃發展，而對健康和福祉的重視正在改變經前症候群的管理方式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Bayer AG
Eli Lilly and Company
GlaxoSmithKline Plc
Pfizer Inc.
AbbVie Inc.
H. Lundbeck A/S
Dr. Reddy's Laboratories Ltd
BASF SE
SHIONOGI & Co. Ltd
Asarina Pharma AB
Teva Pharmaceutical Industries Ltd
Vistagen Therapeutics
Herbalife International of America, Inc.
The Nature's Bounty Co.
Johnson & Johnson Services

結論與建議

簡介目錄

Product Code: SQMIG35I2433

Global Premenstrual Syndrome Treatment Market size was valued at USD 1.44 Billion in 2024 and is poised to grow from USD 1.49 Billion in 2025 to USD 1.95 Billion by 2033, growing at a CAGR of 3.42% in the forecast period (2026-2033).

The global premenstrual syndrome (PMS) treatment market is experiencing growth driven by heightened awareness of PMS and its impact on women's health, alongside an increasing demand for effective treatment options. There is a significant shift toward non-hormonal and integrative therapies, mirroring broader healthcare trends toward personalized, non-invasive treatments. Major pharmaceutical and healthcare companies are actively investing in research and development to introduce innovative therapies. However, the market faces challenges, including regulatory hurdles that hinder treatment approval and accessibility, along with inconsistent treatment protocols leading to varied patient outcomes. As digital health solutions, like mobile apps for PMS management, gain traction, concerns regarding data privacy and security become paramount. Ensuring robust data protection will be critical as the industry evolves alongside technological integration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Premenstrual Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Premenstrual Syndrome Treatment Market Segments Analysis

The global premenstrual syndrome treatment market is segmented into product, drug, distribution channel, and region. by product, the market is classified into Prescription and Over-the-Counter (OTC). Depending on the drug, it is divided into Analgesics, Antidepressants, and Oral Contraceptives & Ovarian Suppression Agents. According to distribution channel, the market is categorized into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Premenstrual Syndrome Treatment Market

The growing awareness surrounding premenstrual syndrome (PMS) and its symptoms has significantly fueled the demand for treatment options in the market. Public awareness campaigns and educational initiatives play a crucial role in enhancing understanding among women regarding PMS, ultimately encouraging them to seek medical advice. Organizations dedicated to this cause, like the International Association for Premenstrual Disorders (IAPMD), actively promote awareness, leading women to healthcare providers. This increased diagnosis of PMS paves the way for a higher demand for various treatment options, including oral contraceptives, thus expanding the scope of the global premenstrual syndrome treatment market.

Restraints in the Global Premenstrual Syndrome Treatment Market

The Global Premenstrual Syndrome Treatment market faces significant challenges due to the stigma surrounding mental health issues associated with PMS, which often leads to underreporting of symptoms. In various cultures, discussing PMS and its related symptoms among women can be considered taboo, resulting in a reluctance to seek treatment or openly address the condition. This cultural reluctance diminishes the demand for effective therapies, such as antidepressants or hormonal treatments, thereby hindering the overall growth of the market. As a result, increased awareness and acceptance are necessary to help overcome these obstacles and expand treatment options for those affected.

Market Trends of the Global Premenstrual Syndrome Treatment Market

The Global Premenstrual Syndrome (PMS) Treatment market is witnessing a notable shift towards natural and holistic solutions, as consumers increasingly prefer herbal and plant-based remedies over traditional pharmaceuticals. This trend reflects a rising awareness of wellness and a desire for drug-free alternatives to alleviate PMS symptoms like cramping and mood swings. The incorporation of natural ingredients such as vitamin B6, calcium, and magnesium not only appeals to consumers seeking sustainable options but also fosters a growing market for innovative herbal treatments. Businesses tapping into this demand are thriving, contributing to a transformative landscape where health and wellness priorities shape PMS management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis

Global Premenstrual Syndrome Treatment Market Size by Product & CAGR (2026-2033)

Market Overview
Prescription
Over-the-Counter (OTC)

Global Premenstrual Syndrome Treatment Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Analgesics
Antidepressants
Oral Contraceptives & Ovarian Suppression Agents

Global Premenstrual Syndrome Treatment Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Drug Stores & Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Global Premenstrual Syndrome Treatment Market Size & CAGR (2026-2033)

North America (Product, Drug Type, Distribution Channel)
- US
- Canada
Europe (Product, Drug Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Drug Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Drug Type, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Drug Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BASF SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SHIONOGI & Co. Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Asarina Pharma AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vistagen Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Herbalife International of America, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
The Nature's Bounty Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments